Literature DB >> 1357542

Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities.

R A Lahti1, L M Figur, M F Piercey, P L Ruppel, D L Evans.   

Abstract

Guanine nucleotide-binding protein-coupled receptors have been shown to exist in both a high affinity agonist (HiAg) and a low affinity agonist (LowAg) state. The formation of the HiAg state is promoted by agonists, and the formation of this state of the receptor appears to be a critical factor in the generation of the effector-activating complex G alpha.GTP.Mg2+ and in the production of a stimulus. The magnitude of the difference in the affinity a compound has for the HiAg versus the LowAg state of the receptor has been related to the intrinsic activity of the compound. In this paper the HiAg and LowAg affinities (Ki) of full and partial dopamine agonists of varying levels of intrinsic activity were determined using membranes from Chinese hamster ovary cells stably transfected with the D2i receptor. The HiAg state was defined using the recently described dopamine agonist ligand [3H]U-86170, and the LowAg state was defined using [3H] raclopride plus 600 microM GTP. The LowAg/HiAg ratios for apomorphine (43), HW-165 (12.5), (-)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine [(-)-3-PPP] (4.5), terguride (1.6), SDZ-208-911 (1.2), and SDZ-208-912 (0.3) were found to correlate well with their electrophysiologically derived intrinsic activities (r = 0.92). Using this relationship, the intrinsic activity for compounds such as (+)-3-PPP (112%), quinpirole (104%), U-68553B (102%), and U-86170 (95%) was predicted to be high (greater than 90%); (-)-apomorphine (73%) was of high/moderate intrinsic activity, HW-165 (52%), (+)-apomorphine (51%), and (-)-3-PPP (34%) were in the intermediate range, and terguride (16.5%), SDZ-208-911 (11.7%), and SDZ-208-912 (-12%) were at the lower end of the intrinsic activity spectrum. The receptor state binding-determined intrinsic activity values for quinpirole (100%), U-86170F (94.8%), HW-165 (52.1%), (-)-3-PPP (34.3%), SDZ-208-911 (11.7%), and SDZ-208-912 (-12%) were found to correlate well (r = 0.908) with their maximum response (intrinsic activity), as determined using ATP-mediated increases in arachidonic acid release from CHO-D2i cells. In addition, the maximal effect of several of these compounds on rat striatal homovanillic acid (HVA) levels was determined. The drug-induced changes in tissue HVA levels were found to be consistent with the affinity-derived intrinsic activities of the drugs.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1357542

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  13 in total

1.  Stimulating and inhibitory effects of the dopamine "stabilizer" (-)-OSU6162 on dopamine D2 receptor function in vitro.

Authors:  R A Lahti; C A Tamminga; A Carlsson
Journal:  J Neural Transm (Vienna)       Date:  2007-07-06       Impact factor: 3.575

2.  Pharmacological characterization of N1-(2-methoxyphenyl)-N4-hexylpiperazine as a multi-target antagonist of α1A/α1D-adrenoceptors and 5-HT1A receptors that blocks prostate contraction and cell growth.

Authors:  Fernanda Chagas-Silva; Jéssica Barbosa Nascimento-Viana; Luiz Antonio S Romeiro; Luana C Barberato; François Noël; Claudia Lucia Martins Silva
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-10       Impact factor: 3.000

3.  Differential modulation by GTPgammaS of agonist and inverse agonist binding to h5-HT(1A) receptors revealed by [3H]-WAY100,635.

Authors:  A Newman-Tancredi; L Verrièle; M J Millan
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 4.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

5.  The substituted (S)-3-phenylpiperidine (-)-OSU6162 reduces apomorphine- and amphetamine-induced behaviour in Cebus apella monkeys.

Authors:  M Brandt-Christensen; M B Andersen; A Fink-Jensen; T Werge; J Gerlach
Journal:  J Neural Transm (Vienna)       Date:  2005-03-30       Impact factor: 3.575

6.  In vivo serotonin-sensitive binding of [11C]CUMI-101: a serotonin 1A receptor agonist positron emission tomography radiotracer.

Authors:  Matthew S Milak; Alin J Severance; Jaya Prabhakaran; J S Dileep Kumar; Vattoly J Majo; R Todd Ogden; J John Mann; Ramin V Parsey
Journal:  J Cereb Blood Flow Metab       Date:  2010-06-23       Impact factor: 6.200

7.  The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity.

Authors:  N Waters; K Svensson; S R Haadsma-Svensson; M W Smith; A Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1993

8.  Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography.

Authors:  Nicholas Seneca; Sjoerd J Finnema; István Laszlovszky; Béla Kiss; Attila Horváth; Gabriella Pásztor; Margó Kapás; István Gyertyán; Sándor Farkas; Robert B Innis; Christer Halldin; Balázs Gulyás
Journal:  Psychopharmacology (Berl)       Date:  2011-05-28       Impact factor: 4.530

9.  Deoxyribose analogues of N6-cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo.

Authors:  R A Mathôt; E M Van der Wenden; W Soudijn; A P IJzerman; M Danhof
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

10.  Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study.

Authors:  Charles R Conway; John T Chibnall; Paul Cumming; Mark A Mintun; Marie Anne I Gebara; Dana C Perantie; Joseph L Price; Martha E Cornell; Jonathan E McConathy; Sunil Gangwani; Yvette I Sheline
Journal:  Psychiatry Res       Date:  2014-01-14       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.